KiraGen Bio and Flash BioSolutions announced a development partnership on April 2, 2024, to use Flash BioSolutions' LentiCare® lentiviral-vector platform in KiraGen's CAR-T work. At the time, KiraGen described KiraLOGIC as a machine-learning system for designing combinations of up to eight tumor-microenvironment-resistance edits and referred to its suppression-resistance approach as TME-Guard.
The collaboration was intended to begin with proof-of-concept work and support subsequent preclinical development. Ryan Murray, PhD, and Aaron Edwards described its role in data generation and progression toward clinical development, while Flash BioSolutions CEO Jérôme Bédier described the company's vector-development and manufacturing contribution.
At the time of the announcement, Flash BioSolutions said its manufacturing platform had 20 years of use across research, preclinical, clinical, and commercial phases. For information from Flash BioSolutions, contact Soraya Sandokchi at +33 582 955 546 or soraya.sandokchi@flashbiosolutions.com.